Lexeo Therapeutics (LXEO) News Today $4.11 +0.12 (+3.01%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$4.07 -0.04 (-0.97%) As of 03/27/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Brokers Set Expectations for LXEO Q1 EarningsMarch 28 at 1:31 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)HC Wainwright reissued a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday.March 27 at 8:26 AM | marketbeat.comQ1 Earnings Forecast for LXEO Issued By Leerink PartnrsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.80) per share for thMarch 27 at 6:27 AM | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Receives Buy Rating from HC WainwrightMarch 27 at 4:21 AM | americanbankingnews.comChardan Capital Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO)March 27 at 2:01 AM | americanbankingnews.comRoyal Bank of Canada Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $20.00Royal Bank of Canada lowered their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday.March 26 at 11:18 AM | marketbeat.comLexeo Therapeutics' (LXEO) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday.March 26 at 8:34 AM | marketbeat.comLexeo Therapeutics price target lowered to $18 from $19 at LeerinkMarch 26 at 5:59 AM | markets.businessinsider.comLexeo Therapeutics price target lowered to $20 from $24 at RBC CapitalMarch 26 at 5:59 AM | markets.businessinsider.comLeerink Partners Cuts Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $18.00March 26 at 1:49 AM | americanbankingnews.comLexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPSLexeo Therapeutics (NASDAQ:LXEO - Get Free Report) announced its earnings results on Monday. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.March 25 at 4:26 PM | marketbeat.comLeerink Partners Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $18.00Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday.March 25 at 12:17 PM | marketbeat.comPharma Frenzy: Volatility Ignites Biotech SectorTwo biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.March 25 at 9:10 AM | marketbeat.comLexeo Therapeutics reports Q4 EPS (78c), consensus (78c)March 25 at 3:08 AM | markets.businessinsider.comLexeo Therapeutics sees cash runway into 2027March 25 at 3:08 AM | markets.businessinsider.comLexeo Therapeutics Advances Genetic Medicine InitiativesMarch 25 at 12:24 AM | tipranks.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational HighlightsMarch 24, 2025 | globenewswire.comPrivium Fund Management B.V. Takes $909,000 Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Privium Fund Management B.V. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 138,115 shares of the company's stock, valued at approximately $909,000. Privium FundMarch 20, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) and Monte Rosa Therapeutics (NASDAQ:GLUE) Financial AnalysisMarch 18, 2025 | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given a consensus rating of "Buy" by the six analysts that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the companMarch 8, 2025 | marketbeat.comShort Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 22.9%Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 2,310,000 shares, a growth of 22.9% from the January 31st total of 1,880,000 shares. Currently, 9.2% of the company's stock are short sold. Based on an average daily trading volume, of 256,500 shares, the short-interest ratio is currently 9.0 days.March 7, 2025 | marketbeat.comLexeo Therapeutics (LXEO) to Release Quarterly Earnings on MondayLexeo Therapeutics (NASDAQ:LXEO) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $19,077.66 in StockLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 4,326 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $4.41, for a total transaction of $19,077.66. Following the sale, the chief executive officer now directly owns 220,119 shares in the company, valued at $970,724.79. This represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.February 22, 2025 | marketbeat.comRichard Nolan Townsend Sells 4,326 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) StockFebruary 22, 2025 | insidertrades.comTop Executives at Lexeo Therapeutics Cash In on Stock Sales!February 21, 2025 | tipranks.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Down 18.6% in JanuaryLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 1,880,000 shares, a decrease of 18.6% from the January 15th total of 2,310,000 shares. Approximately 8.0% of the shares of the company are short sold. Based on an average trading volume of 352,500 shares, the short-interest ratio is presently 5.3 days.February 16, 2025 | marketbeat.comLexeo stock hits 52-week low at $4.23 amid market challengesFebruary 11, 2025 | msn.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strongFebruary 11, 2025 | marketbeat.comLexeo Therapeutics, Inc. (LXEO) Gets a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comLeerink Partnrs Has Bullish Outlook for LXEO FY2026 EarningsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs increased their FY2026 earnings per share estimates for Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company wJanuary 24, 2025 | marketbeat.comLexeo stock touches 52-week low at $4.76 amid market challengesJanuary 23, 2025 | msn.comRBC Capital Sticks to Their Buy Rating for Lexeo Therapeutics, Inc. (LXEO)January 21, 2025 | markets.businessinsider.comLexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday.January 21, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strongJanuary 17, 2025 | marketbeat.comSolid Biosciences stock jumps 11% post-market on FDA updateJanuary 7, 2025 | msn.comLexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comGeode Capital Management LLC Increases Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Geode Capital Management LLC increased its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 86.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 553,247 shares of the company'sJanuary 5, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average rating of "Buy" by the six research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy reDecember 23, 2024 | marketbeat.comLexeo Therapeutics Appoints Dr. Kyle Rasbach as CFODecember 20, 2024 | markets.businessinsider.comLexeo Therapeutics Appoints Kyle Rasbach As CFODecember 19, 2024 | markets.businessinsider.comLexeo Therapeutics Names Kyle Rasbach Chief Financial OfficerDecember 19, 2024 | marketwatch.comLexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerDecember 19, 2024 | globenewswire.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $20,500.00 in StockDecember 13, 2024 | insidertrades.comFrazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Frazier Life Sciences Management L.P. bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,250,786 shares of the company'sDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Acquires Shares of 370,407 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Point72 Asset Management L.P. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 370,407 shares of the company's stock, valued at approximately $December 10, 2024 | marketbeat.comJanus Henderson Group PLC Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Janus Henderson Group PLC raised its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,763,195 shares of the company's stock after acquiring anDecember 7, 2024 | marketbeat.comRA Capital Management L.P. Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)RA Capital Management L.P. lessened its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 546,554 shares of the company's stocDecember 5, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Bought by Verition Fund Management LLCVerition Fund Management LLC grew its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 84.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 777,320 shares of the company's stock after purchasing an addDecember 2, 2024 | marketbeat.comBraidwell LP Sells 653,704 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Braidwell LP cut its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 47.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 728,777 shares of the company's stock after sNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Reduces Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Eventide Asset Management LLC lowered its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 44.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,855,986 shares of the company's stock after selling 1,513,161 shares during the period. Eventide AsNovember 29, 2024 | marketbeat.com Remove Ads Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.400.78▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼252▲LXEO Articles Average Week Remove Ads Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mereo BioPharma Group News Today SNDL News Today Entrada Therapeutics News Today SIGA Technologies News Today Eton Pharmaceuticals News Today Kamada News Today Allogene Therapeutics News Today Arcturus Therapeutics News Today Revance Therapeutics News Today ABIVAX Société Anonyme News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXEO Stock Free LXEO Stock Alerts